Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury
Ruxiang Sheng, Yanqiu Liang, Huihong Zhang, Yonghe Lai, Haiyun Hong, Dingbang Huang, Dezhao Liu · 2026
Read Bioinformatics-driven insights: rapamycin-mediated CaMK2D inhibition alleviates intestinal ischemia-reperfusion injury by Ruxiang Sheng, Yanqiu Liang, Huihong Zhang, Yonghe Lai, Haiyun Hong, Dingbang Huang, Dezhao Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13175813.txt.
Description
Ruxiang Sheng and co-authors trace how rapamycin eases gut injury in a 2026 study. Intestinal ischemia-reperfusion injury strikes when blood returns to a starved gut, and it kills often. The team's earlier work showed targeted nano-delivery could carry rapamycin to the injury site with benefit.
A protein kinase called CaMK2D, known in heart injury and tumors, had no known role in gut injury. Cell models starved of oxygen and sugar, plus a mouse gut injury model, test that role here. Data-driven analysis points to rapamycin calming the kinase pathway. A named mechanism turns a drug observation into a target. Future gut drugs could aim at the same switch.
Catalog record
| CREATOR | Ruxiang Sheng, Yanqiu Liang, Huihong Zhang, Yonghe Lai, Haiyun Hong, Dingbang Huang, Dezhao Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |